


# **Study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer**

November 12 2020

---

## JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK



### NCCN Guidelines®

• CENTRAL NERVOUS SYSTEM CANCERS

### NCCN Guidelines® Insights

• T-CELL LYMPHOMAS

#### ONCOLOGY WATCH

Lasting Effects of COVID-19: Reimbursement Reform?  
*Tempero M*

#### COMMENTARY

Lessons From Adaptive Randomization:  
Spying the I-SPY2 Trial in Breast Cancer  
*Gyawali B and Niraula S*

#### THE LAST WORD

The Internet as a Route to Health Information,  
Support, and Healthcare for Cancer Survivors  
*Bender JL*

#### MOLECULAR INSIGHTS IN PATIENT CARE

Molecular Insights in Transmission of Cancer From  
an Organ Donor to Four Transplant Recipients  
*Atreya CE, Collisson EA, Park M, et al*

#### REVIEWS

Challenges in the Treatment of Newly  
Diagnosed and Recurrent Primary  
Central Nervous System Lymphoma  
*Holdhoff M, Mrugala MM, Grommes C, et al*

Proposed Additions to the  
NCCN Guidelines for Adult Medulloblastoma  
*Penas-Prado M, Armstrong TS, and Gilbert MR*

#### ORIGINAL RESEARCH

General and Health-Related Internet Use Among  
Cancer Survivors in the United States:  
A 2013–2018 Cross-Sectional Analysis  
*Dee EC, Muralidhar V, Butler SS, et al*

Role of Postoperative Radiotherapy in Nonmetastatic  
Head and Neck Adenoid Cystic Carcinoma  
*Chen Y, Zheng Z-Q, Chen F-P, et al*

Prostate Cancer Grade and Stage  
Misclassification in Active Surveillance  
Candidates: Black Versus White Patients  
*Stolzenbach LF, Rosiello G, Pecoraro A, et al*

A New Surveillance Algorithm After Resection of  
Colorectal Liver Metastases Based on Changes in  
Recurrence Risk and RAS Mutation Status  
*Kawaguchi Y, Kopetz S, Lillemoe HA, et al*

Use of <sup>18</sup>F-FDG PET/CT as an Initial Staging  
Procedure for Stage II–III Breast Cancer:  
A Multicenter Value Analysis  
*Hyland CJ, Varghese F, Yau C, et al*

Validating a Patient-Reported, Outcomes-Derived  
Algorithm for Classifying Symptom Complexity  
Levels Among Patients With Cancer  
*Watson L, Qi S, Delure A, et al*

Cost-Effectiveness of Maintenance Olaparib for  
Germline BRCA-Mutated Metastatic Pancreatic Cancer  
*Wu B and Shi L*

Studies have shown that utilizing a PARP inhibitor in the management of patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations is clinically beneficial. New research in the November 2020 issue of *JNCCN—Journal of the National Comprehensive Cancer Network* sheds further light on this subject through cost-effectiveness analysis. The investigators seek to identify patient subgroups with the highest relative cost-effectiveness, through models based on efficacy and toxicity data from the Pancreas Cancer Olaparib Ongoing (POLO) trial, and measuring it against cost per quality-adjusted life year (QALY).

"With the present clinical evidence, olaparib should be prescribed for patients with metastatic [pancreatic](#) cancer harboring a germline BRCA 1/2 mutation, especially after the first-line platinum-based chemotherapy has been successfully completed," said researcher Lizheng Shi, Ph.D., School of Public Health and Tropical Medicine, Tulane University. "Our [economic analysis](#) found that olaparib might be a cost-effective option for patients, particularly if we select for optimal sub-groups, such as those who completed at least 16 weeks of continuous first-line platinum-based chemotherapy."

Bin Wu, Ph.D., of Shanghai Jiaotong University in China, who co-authored this study also pointed out: "The cost-effectiveness of olaparib as measured by cost-per-QALY is reasonably close to the commonly used willingness-to-pay thresholds. The value of olaparib maintenance would be even more attractive if the price were lower."

The researchers calculated incremental cost-utility ratios (ICUR) for patients taking maintenance olaparib versus those taking a placebo. Medical [costs](#) included drug acquisition, costs attributed to health states,

costs for managing adverse effects, and costs for end-of-life care. All were calculated and considered based on 2018 U.S. dollar values. Modeling suggested that maintenance olaparib would be cost-effective in certain scenarios, using a threshold of \$200,000 per QALY gained.

"While there is emerging evidence that precision medicine is relevant to subsets of patients with advanced pancreatic cancer, definitive results to support the cost-effectiveness of maintenance olaparib is lacking," commented Robert A. Wolff, MD, The University of Texas MD Anderson Cancer Center. Dr. Wolff is a member of the NCCN Guidelines Panel for Pancreatic Adenocarcinoma and was not involved in this study. "Cost-effectiveness analyses of PARP inhibitors used in similar patient populations with recurrent ovarian cancer have been negative. Thus, either improved patient selection for maintenance olaparib or reduced drug costs are likely necessary to establish [olaparib](#) as a cost-effective therapy in metastatic pancreatic [cancer](#)."

**More information:** Bin Wu et al, Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer, *Journal of the National Comprehensive Cancer Network* (2020). [DOI: 10.6004/jnccn.2020.7587](#)

Provided by National Comprehensive Cancer Network

Citation: Study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer (2020, November 12) retrieved 2 May 2024 from <https://medicalxpress.com/news/2020-11-cost-effectiveness-olaparib-metastatic-pancreatic-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
---